Amsterdam, Jan 29 (efe-epa).- The European Medicines Agency on Friday announced it had not identified any new side effects of the Pfizer-BioNTech Covid-19 vaccine in the first month of its rollout in the European Union.
The report added that the vaccine, known as Comirnaty, had not been linked to any deaths in patients after receiving the jab.
“Data collected on Comirnaty use in vaccination campaigns is consistent with the known safety profile of the vaccine, and no new side effects were identified,” the EMA report said.
Anaphylaxis was identified as a possible side effect of the vaccine in clinical trials.
“The benefits of Comirnaty in preventing Covid-19 continue to outweigh any risks, and there are no recommended changes regarding the use of the vaccine.”
The EMA’s security committee (PRAC) studied reports in Norway of older patients who died after receiving the Pfizer jab, but found no safety concerns linked to the vaccine in these cases.
“In many cases concerning individuals above 65 years of age, progression of (multiple) pre-existing diseases seemed to be a plausible explanation for death. In some individuals, palliative care had already been initiated before vaccination,” the report said.
“No specific safety concern has been identified for vaccine use in frail elderly individuals.
“The safety and effectiveness of Comirnaty will continue to be monitored as it is used across the Member States and globally,” the EMA added. EFE-EPA